ERBB2 and breast cancer: Using the Surveillance, Epidemiology, and End Results (SEER) registries, which cover about 35% of the US population as a whole and have documented HER2 status since 2010 for breast cancer cases, the present study expands these findings by examining disparities in risk of breast cancer-specific mortality across multiple racial and ethnic groups.